7-2-2012 Digitalis voor kanker? Geen zelf -experimenten!!
Digitalis, a targeted therapy for cancer? Not to use on your own!! Dutch physician Dr.A.J Houtsmuller was " given up" by his colleagues
..................It is reasonable to expect that the addition of digitalis to current cancer treatments will improve the clinical outcomes.
I saw this mentioned for the first time ago some 10-15b years ago in the book of a Dutch physician Dr.A.J Houtsmuller who was " given up" [ melanoma stage 3 according to Clark with metastases in the right kidney] by his colleagues and wrote the book [ title translated by me] : Non-toxic Tumor therapy
Am J Med Sci. 2009 May;337(5):355-9.
Digitalis, a targeted therapy for cancer?
Khan MI, Chesney JA, Laber DA, Miller DM.
Source
Department of Medicine, Division of Medical Oncology and Hematology, University of Louisville, Louisville, KY 40202, USA.
Abstract
The clinical benefit of digitalis for patients with heart disease is well established. However, recent studies have also suggested that digitalis has antineoplastic activities at clinically relevant serum concentrations. Much of the early evidence supporting the anticancer activity of digitalis has been circumstantial. Observational studies suggest a protective benefit and improved outcomes in patients who develop cancer while they are taking digitalis. The mechanism by which digitalis selectively affects the growth of malignant cells is complex, involving several important signaling pathways. Experiments to determine its mechanism of action have demonstrated that digitalis inhibits cell growth and angiogenesis and induces apoptosis in multiple cancer cell lines. Most, if not all, of these effects are mediated through its target enzyme, sodium- and potassium-activated adenosine triphosphatase. This article reviews the literature, which supports the use of digitalis in patients with malignancies with a discussion of the potential mechanisms of action. We hypothesize that sodium- and potassium-activated adenosine triphosphatase is an important new target for cancer therapy. It is reasonable to expect that the addition of digitalis to current cancer treatments will improve the clinical outcomes.
PMID: 19440057 [PubMed - indexed for MEDLINE]
Digitalis, a targeted therapy for cancer?
Khan MI, Chesney JA, Laber DA, Miller DM.
Source
Department of Medicine, Division of Medical Oncology and Hematology, University of Louisville, Louisville, KY 40202, USA.
Abstract
The clinical benefit of digitalis for patients with heart disease is well established. However, recent studies have also suggested that digitalis has antineoplastic activities at clinically relevant serum concentrations. Much of the early evidence supporting the anticancer activity of digitalis has been circumstantial. Observational studies suggest a protective benefit and improved outcomes in patients who develop cancer while they are taking digitalis. The mechanism by which digitalis selectively affects the growth of malignant cells is complex, involving several important signaling pathways. Experiments to determine its mechanism of action have demonstrated that digitalis inhibits cell growth and angiogenesis and induces apoptosis in multiple cancer cell lines. Most, if not all, of these effects are mediated through its target enzyme, sodium- and potassium-activated adenosine triphosphatase. This article reviews the literature, which supports the use of digitalis in patients with malignancies with a discussion of the potential mechanisms of action. We hypothesize that sodium- and potassium-activated adenosine triphosphatase is an important new target for cancer therapy. It is reasonable to expect that the addition of digitalis to current cancer treatments will improve the clinical outcomes.
PMID: 19440057 [PubMed - indexed for MEDLINE]